News FDA clears first at-home device for depression Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.
News J&J adds first new indication for Caplyta since takeover Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.
News Psychedelic merger to create AtaiBeckley completes A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.
News Rumour partly confirmed as AbbVie acquires Gilgamesh drug Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.
News Is AbbVie planning an epic Gilgamesh takeover? AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.
News Beckley psychedelic hits the target, unlocking atai merger The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
